NCT02064387 (Clinical Trial / GSK2857916 / J6M0-mcMMAF)

Study Title
Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916 (NCT02064387)

Trial Description
This study will assess the safety, pharmacokinetic (PK), pharmacodynamic (PD) and the therapeutic potential of GSK2857916 (J6M0-mcMMAF) in subjects with multiple myeloma (MM) and other hematologic malignancies that express B cell maturation antigen (BCMA). The hypothesis is that GSK2857916 can be safely administered to subjects with BCMA positive malignancies at doses where target engagement can be demonstrated. This study will determine if adequate target engagement of BCMA receptors translates into clinical benefit for subjects with MM and other BCMA positive hematologic malignancies. The study will consists of two parts: a Part 1 dose escalation phase and a Part 2 expansion phase for safety, and clinical activity testing. The study will enroll a total of approximately 80 subjects with relapsed/refractory MM or other BCMA-expressing hematologic malignancies.

This trial is sponsored by GlaxoSmithKline. [1]

Study Data

  • Condition: Multiple Myeloma
  • Interventions:
    • Drugs used in this trial
      • GSK2857916 (J6M0-mcMMAF)
  • Phase: I
  • Estimated Enrollment: 85
  • Start: July 2014
  • Estimated Completion: August 2016
  • Last verified: October 2017

Study Schematic 


Last Editorial review: November 2017
Information based on (NIH/NCI) and other sources.

Copyright © 2015-2017 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.